Skip to main content
HR 6043 114th Congress House Health Civil actions and liability Congressional oversight Consumer affairs Corporate finance and management Government information and archives Government studies and investigations Inflation and prices Medical research Prescription drugs Research and development

Fair Accountability and Innovative Research Drug Pricing Act of 2016

Introduced: September 15, 2016 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 15, 2016
Referred to the House Committee on Energy and Commerce.
Sep 15, 2016
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Fair Accountability and Innovative Research Drug Pricing Act of 2016

This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the price of a drug over a 12-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1.

Manufacturers that do not submit a required report are subject to a civil penalty. The Inspector General of HHS must review drug price information to determine compliance. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.

HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.
What's happening now September 15, 2016

Referred to the House Committee on Energy and Commerce.

 Related & companion bills 1
  • S 3335 Identical bill Fair Accountability and Innovative Research Drug Pricing Act of 2016
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 9
All 9 Democratic 9
D
Pingree, Chellie
Maine · Nov 14, 2016
 D
Lynch, Stephen F.
Massachusetts · Sep 26, 2016
 D
Moore, Gwen
Wisconsin · Sep 26, 2016
 D
Castor, Kathy
Florida · Sep 20, 2016
 D
Nadler, Jerrold
New York · Sep 20, 2016
 D
Pocan, Mark
Wisconsin · Sep 20, 2016
 D
DeLauro, Rosa L.
Connecticut · Sep 15, 2016
 D
Doggett, Lloyd
Texas · Sep 15, 2016
 D
Welch, Peter
Vermont · Sep 15, 2016
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6043: Fair Accountability and Innovative Research Drug Pricing Act of 2016. 114th Congress. Open America. https://openamerica.io/bill/114-HR-6043/
MLA
"H.R. 6043: Fair Accountability and Innovative Research Drug Pricing Act of 2016." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-6043/.
Bluebook (legal)
H.R. 6043, 114th Cong. (2026), https://openamerica.io/bill/114-HR-6043/.
Markdown link
[H.R. 6043: Fair Accountability and Innovative Research Drug Pricing Act of 2016](https://openamerica.io/bill/114-HR-6043/)
Report a problem